Author name: Beth Washington

inventor-claims-bleach-injections-will-destroy-cancer-tumors

Inventor claims bleach injections will destroy cancer tumors


A lack of medical training isn’t stopping a man from charging $20,000 for the treatment.

Credit: Aurich Lawson | Getty Images

Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for access to an AI-driven but entirely unproven treatment that includes injecting a highly concentrated dose of chlorine dioxide, a toxic bleach solution, directly into cancerous tumors.

One patient tells WIRED her tumor has grown faster since the procedure and that she suspects it may have caused her cancer to spread—a claim Liu disputes—while experts allege his marketing of the treatment has likely put him on the wrong side of US regulations. Nonetheless, while Liu currently only offers the treatment informally in China and at a German clinic, he is now working with a Texas-based former pharmaceutical executive to bring his treatment to America. They believe that the appointment of Robert F. Kennedy Jr. as US health secretary will help “open doors” to get the untested treatment—in which at least one clinic in California appears to have interest—approved in the US.

Kennedy’s Make America Healthy Again movement is embracing alternative medicines and the idea of giving patients the freedom to try unproven treatments. While the health secretary did not respond to a request for comment about Liu’s treatment, he did mention chlorine dioxide when questioned about President Donald Trump’s Operation Warp Speed during his Senate confirmation hearing in February, and the Food and Drug Administration recently removed a warning about the substance from its website. The agency says the removal was part of a routine process of archiving old pages on its site, but it has had the effect of emboldening the bleacher community.

“Without the FDA’s heavy-handed warnings, it’s likely my therapy would have been accepted for trials years earlier, with institutional partnerships and investor support,” Liu tells WIRED. He says he wrote to Kennedy earlier this year urging him to conduct more research on chlorine dioxide. “This quiet removal won’t immediately change everything, but it opens a door. If mainstream media reports on this shift, I believe it will unlock a new wave of serious [chlorine dioxide] research.”

For decades, pseudoscience grifters have peddled chlorine dioxide solutions—sold under a variety of names, such as Miracle Mineral Solution—and despite warnings and prosecutions have continued to claim the toxic substance is a “cure” for everything from HIV to COVID-19 to autism. There is no credible evidence to back up any of these claims, which critics have long labeled as nothing more than a grift.

The treatments typically involve drinking liquid chlorine dioxide on a regular basis, using solutions with concentrations of chlorine dioxide of around 3,000 parts per million (ppm), which is diluted further in water.

Liu’s treatment, however, involves a much higher concentration of chlorine dioxide—injections of several millilitres of 20,000 ppm—and, rather than drinking it, patients have it injected directly into their tumors.

I injected myself to test it

Liu claims he has injected himself with the solution more than 50 times and suffered no side effects. “This personal data point encouraged me to continue research,” he says.

Liu has been making the solution in his rented apartment in Beijing by mixing citric acid with sodium chlorite, according to an account he shared earlier this month on his Substack that revealed that a “violent explosion” occurred when he made a mistake.

“The blast blacked out my vision,” Liu wrote. “Dense clouds of chlorine dioxide burst into my face, filling my eyes, nose, and mouth. I stumbled back into the apartment, rushing to the bathroom to wash out the gas from my eyes and respiratory tract. My lungs were burning. Later, I would find 4–5 cuts on my upper thigh—shards of glass had pierced through my pants.” Liu also revealed that his 3-year-old daughter was nearby when the explosion happened.

Liu began a preclinical study on animals in 2016, before beginning to use the highly concentrated solution to treat human patients in more recent years. He claims that between China and Germany, he has treated 20 patients to date.

When asked for evidence to back up his claims of efficacy, Liu shared links to a number of preprints, which have not been peer-reviewed, with WIRED. He also shared a pitch deck for a $5 million seed round in a US-focused startup that would provide the chlorine dioxide injections.

The presentation contains a number of “case studies” of patients he has treated—including a dog—but rather than featuring detailed scientific data, the deck contains disturbing images of the patients’ tumors. The deck also contains, as evidence of the treatment’s efficacy, a screenshot of a WhatsApp conversation with a patient who was apparently treating a liver tumor with chlorine dioxide.

“Screenshots of WhatsApp chats with patients or their doctors is not evidence of efficacy, yet that is the only evidence he provides,” says Alex Morozov, an oncologist who has overseen hundreds of drug trials at multiple companies including Pfizer. “Needless to say, until appropriate studies are done and published in peer-reviewed journals, or presented at a reputable conference, no patients should be treated except in the context of clinical trials.”

WIRED spoke to a patient of Liu’s, whose descriptions of the treatment appear to undermine his claims of efficacy and raise serious questions about its safety.

“I bought the needles online and made the chlorine dioxide by myself [then] I injected it into the tumor and lymph nodes by myself,” says the patient, a Chinese national living in the UK. WIRED granted her anonymity to protect her privacy.

The patient had previously been taking oral solutions of chlorine dioxide as an alternative treatment for cancer, but, unsatisfied with the results, she contacted Liu via WhatsApp. On a spring evening last year, she took her first injection of chlorine dioxide and, she says, almost immediately suffered negative side effects.

“It was fine after the injection, but I was woken up by severe pain [like] I had never experienced in my life,” she says. “The pain lasted for three to four days.”

Despite the pain, she says, she injected herself again two months later, and a month after that she traveled to China, where Liu, despite having no medical training, injected her, using an anesthetic cream to numb the skin.

“While this act technically fell outside legal boundaries, in China, if the patient is competent and gives informed consent, such compassionate-use interventions rarely attract regulatory attention unless harm is done,” Liu tells WIRED.

Legal in China?

Experts on Chinese medical regulations tell WIRED that new treatments like Liu’s would have to meet strict conditions before they can be administered to patients. “It would have to go through the same steps in China as it does in the US, so that will involve clinical studies, getting ethics approval at the hospitals, and then the situation would have to be reviewed by the Chinese government,” Ames Gross, founder and president of Pacific Bridge Capital, tells WIRED. “I don’t think any of it sounds very legal.” The Chinese Ministry of Foreign Affairs, which handles all international press inquiries, did not respond to a request for comment.

As well as the initial pain, the chlorine dioxide injections also appear, the patient says, to have made the cancer worse.

“The tumor shrinks first, then it grows faster than before,” she says, adding: “My tumor has spread to the skin after injection. I suspect it is because the chlorine dioxide has broken the vein and the cancer cells go to the skin area.”

Liu did not agree with this assessment, instead blaming the fact that the patient had not completed the full course of four injections within a month, as he typically prescribes.

The patient says that thanks to a WeChat group that Liu set up, she is also in contact with other people who have had chlorine dioxide injections. One of the women, who is based in Shenzhen, China, had at least one injection of chlorine dioxide to treat what was described as vaginal cancer, but she says she is also suffering complications, according to screenshots of conversations reviewed by WIRED.

“After the injection, there was swelling and difficulty urinating,” the Chinese woman wrote. “It was very uncomfortable.”

Despite having injected a patient in China last August, Liu tells WIRED, he is not a licensed physician—he calls himself “an independent inventor and medical researcher.” The treatment, which he says is “designed to be administered by licensed physicians in clinical settings,” is so painful that it needs to be given under general anesthetic.

While Liu’s website says the treatment is being offered at clinics in Mexico, Brazil, and the Philippines, he tells WIRED that the treatment is currently only being offered at the CMC Rheinfelden clinic on the German-Swiss border. Liu features Dr. Wolfgang Renz from the clinic on his own website as one of his partners; the clinic itself does not advertise the treatment on its own website.

In conversations on WhatsApp shared with WIRED, a representative of the clinic named Lena told a prospective patient that it didn’t advertise the chlorine dioxide procedure because it was “not a legal treatment.” Lena later wrote that chlorine dioxide was not referenced on an invoice the clinic sent the same prospective patient because it is “not a legal treatment.” Lena also told the prospective patient that they had treated patients from France, Italy, and the US, according to a recording of a phone call shared with WIRED. One Italian woman is currently trying to raise money to fund her treatment in the German clinic on GoFundMe.

When asked about her comments, Lena told WIRED, “Either [the patient] misquoted me or my English was not very accurate. I repeatedly told [the patient] that it is not an approved therapy and therefore requires very detailed consent and special circumstances to be eligible for this treatment.” The prospective patient was told that she would need to bring documents detailing her prior treatment.

Renz did not respond to multiple requests for comment.

Lena also says that patients who have exhausted every other possible treatment have “the right to be treated with non-approved interventions under strict ethical conditions, full medical supervision, and informed patient consent.” The Federal Institute for Drugs and Medical Devices, which regulates medical products in Germany, did not respond to a request for comment, but Liu tells WIRED that German authorities are investigating a complaint about the clinic.

Expanding across the Pacific

Liu now appears laser-focused on making his treatment available in the US. Despite the lack of clinical data to back up his claims, Liu claims to have signed up over 100 US patients to take part in a proposed clinical research program. Liu shared a screenshot with WIRED including what appeared to be patients’ full names, zip codes, and the type of cancer they are suffering from. It’s unclear if any of the patients had agreed to have their information shared with a journalist.

Liu says he has recruited most of his potential patients via his own website. “Are You a U.S. Cancer Patient? Join the National Campaign to legalize a breakthrough therapy,” a popup that sometimes appears on Liu’s website reads, urging visitors to fill out a patient advocacy application to potentially become part of a clinical trial.

One of those who signed up is Sarah Jones, who has been diagnosed with stage 4 anal cancer that has metastasized to the lymph nodes. Jones, whose identity WIRED is protecting with a pseudonym, has already been treated with chemotherapy and drugs like cisplatin and paclitaxel. The chemotherapy originally caused the tumor to shrink, but it has since returned, and Jones is now seeking alternative treatments.

“I spend my days treating this disease like a job. Red light therapy, guided meditations, exercising, eating a keto-strong diet, and researching,” Jones tells WIRED. “This is how I stumbled upon Liu and his intratumoral injections.”

Despite signing up for a potential trial, Jones understands the risks but feels as if she is running out of choices. “I am extremely concerned that there are but a handful of patients and no data to speak of for this procedure,” Jones says. “I am debating all of my options and am constantly looking for anything that can help.”

This sentiment was echoed by Kevin, whose father has neck cancer and who also signed up as a potential patient for the trial. “If you’re in any cancer patient’s shoes, if you’re out of options, what else do you have to do? You either keep trying new therapies, or you die.”

Another US-based patient with untreated colon cancer who signed up on Liu’s website was informed that they should consider traveling to Germany for treatment, according to a screenshot of an email response from Liu, shared with WIRED. The email outlined that the cost would be €5,000 per injection, adding that “typically 4 injections [are] recommended.”

When the conversation moved to WhatsApp, Liu asked the patient what size the tumor was. The patient, who was granted anonymity to protect their privacy, told Liu the tumor was 3.8 centimeters, according to a screenshot of the WhatsApp conversation reviewed by WIRED.

Liu responded with inaccurate details and information that the patient did not share. Liu also referred to a rectal tumor rather than a colon tumor.

When the patient said they didn’t have the money to travel to Europe for the treatment and asked about getting it in the US, referencing the Williams Cancer Institute in Beverly Hills, California, Liu suggested contacting the clinic directly.

The clinic has indicated its interest in Liu’s unproven procedure by writing about Liu’s chlorine dioxide injection protocol on its own website and mentioned it on a post on its Facebook page. Liu tells WIRED that he has spoken to Jason Williams, director of the clinic. “He is very interested and is a pioneer in the field of intratumoral injections,” Liu says. “His clinic is fully capable of implementing my therapy.”

Neither Williams nor his colleague Nathan Goodyear, who Liu also says he spoke to, responded to repeated emails and phone calls seeking comment.

Liu also gave WIRED the names of a radiologist in California, an anesthesiologist in Seattle, and a physician in Missouri who he claims to have spoken to about providing his treatment in the US, but none of them responded to requests for comment.

The Chinese inventor did, however, appear on a livestream with two US-based doctors, Curtis Anderson, a Florida-based physician, and Mark Rosenberg, who works at the Institute for Healthy Aging. The discussion, hosted on Liu’s YouTube channel, saw the two doctors ask about which cancers to treat with the injections, how to buy chlorine dioxide, or even whether it’s possible to make it themselves.

Rosenberg and Anderson did not respond to requests for comment.

Maybe RFK Jr. will dig it?

Conducting a clinical trial of a new drug in the US requires approval from the Food and Drug Administration. Liu initially claimed to WIRED that “according to Article 37 of the Declaration of Helsinki and the US Right to Try laws, my therapy is already legally permissible in the United States.” Legal experts WIRED spoke to disagree strongly with Liu’s assertions.

“It sounds like Mr. Liu may not understand how the Right to Try Act or the Declaration of Helsinki work or how they fit within the broader context in which the FDA regulates investigational drugs,” Clint Hermes, an attorney with Bass, Berry & Sims, with extensive expertise in biomedical research, tells WIRED. “If he is under the impression that the ‘breast cancer trial’ referenced on his website is sufficient on its own to allow him to market or study his therapy in the US under right to try and/or the Declaration of Helsinki, he is mistaken.”

Even advertising the efficacy of an unproven treatment could land Liu in trouble, according to the American Health Law Association (AHLA).

“Companies cannot make claims regarding safety or efficacy until their products have been approved for marketing by the FDA,” Mary Kohler, a member of the AHLA’s Life Science leadership team, tells WIRED. “From a quick glance at the website, I see several claims that FDA’s Office of Prescription Drug Promotion (OPDP) would likely consider violative as pre-approval promotion even if this company were in trials that FDA was overseeing.”

The FDA and the Department of Health and Human Services did not respond to requests for comment.

When asked about these issues, Liu clarified that he was planning to initially conduct a 100-person “clinical research program” that would not require FDA approval, but Liu’s treatment doesn’t appear to meet any of the most common exemptions that would allow such a trial to take place, according to the FDA’s own website.

Liu also says he is working with “patient advocates” and leveraging their local connections to lobby state lawmakers in “liberty-leaning states” to allow the experimental treatment to be administered. This would appear to circumvent federal rules. Liu says that he has yet to make contact with such a lawmaker directly.

While he has no approval from US government agencies or support of a state or national lawmaker, Liu does have the full backing of Scott Hagerman, an entrepreneur and former executive with 30 years experience in the pharmaceutical industry, including a decade working at Pfizer.

“It’s an unbelievable breakthrough,” Hagerman tells WIRED, adding that he and his wife have been using oral chlorine dioxide solution “for some time” as a preventative measure rather than to treat a specific ailment.

Hagerman’s time in the pharmaceutical industry included over a decade running a company called Chemi Nutra, which has in the past received a US patent for a soy-based supplement that addresses testosterone decline in men. He also says he oversaw teams of scientists who worked on drug applications to the FDA for oncology drugs.

Hagerman retired from Chemi Nutra in 2021, and in the intervening years his comments indicate that he appears to have become entirely disillusioned with the modern pharmaceutical industry, referring to it as a “drugs cartel” and “a corrupt entity that is only profit-driven.” One of the issues Hagerman references is the COVID-19 vaccine based on mRNA technology, which he describes as a “con job” while also boosting the debunked theory that childhood vaccines are linked to increasing levels of autism reported in the population.

As a result, he sees Liu’s lack of experience as a positive.

“I would welcome the fact that he’s not a doctor, that he’s not an MD, because he’s not clouded, jaded, and biased with all kinds of misguidance that would push them the wrong way,” Hagerman says, adding, “I’d like to help him establish some network here in the US, because obviously the US is where the action is.” Hagerman says he is “100 percent sure” that there would be investors willing to fund the development of this treatment.

When asked about a timeline to have this procedure legally available in the US, Hagerman said he hopes it could be achieved before the end of 2025. Liu, however, thinks it could take slightly longer, saying that he believes clinical trials will begin in 2026.

This story originally appeared on wired.com.

Photo of WIRED

Wired.com is your essential daily guide to what’s next, delivering the most original and complete take you’ll find anywhere on innovation’s impact on technology, science, business and culture.

Inventor claims bleach injections will destroy cancer tumors Read More »

new-“applecare-one”-plan-bundles-three-extended-warranties-for-$20-a-month

New “AppleCare One” plan bundles three extended warranties for $20 a month

AppleCare One can also be extended to other Apple products you own “that are up to four years old” (or one year old for headphones) and “in good condition,” even if they’re outside of the typical 60-day grace period for subscribing to AppleCare+. Apple says that the condition of these devices may need to be verified “using a customer’s iPhone or iPad, or at an Apple Store” before they can be added to the plan, presumably to reduce the number of people who opt in after the fact to avoid pricey repairs to already damaged devices.

While the potential savings are the best argument in favor of the new plan, it also adds a handful of new benefits for some devices. For example, AppleCare One covers theft for both iPads and Apple Watches, something that isn’t covered for these devices under a standard AppleCare+ subscription. The subscription can also simplify the trade-in process, removing a traded-in device from your AppleCare One plan and replacing it with an upgraded device automatically.

If you haven’t subscribed to AppleCare+ before, it functions both as an extended warranty and an insurance program. If your device breaks suddenly for reasons outside of your control, repairs and replacements are generally free of additional charge; for accidental damage, theft and loss, or battery replacements, users are charged additional flat service fees for repairs and replacements, rather than Apple’s hefty parts and labor costs. Battery replacements are also free when your battery drops below 80 percent of its original capacity.

AppleCare One plans will go on sale starting tomorrow, July 24.

New “AppleCare One” plan bundles three extended warranties for $20 a month Read More »

audi-has-a-new-midsize-ev,-and-we’ve-driven-it:-the-2025-a6-sportback

Audi has a new midsize EV, and we’ve driven it: The 2025 A6 Sportback

Audi S6 drives on a straight road past vineyards

Long straight roads glide underneath. Credit: Audi

The car’s cabin layout and ergonomics are starting to feel familiar at this point—it shares much not only with the electric Q6 e-tron but also Audi’s new midsize combustion cars, the A5 and Q5. (We’ll leave for now the fact that a combustion A6, unrelated to today’s vehicle in virtually all but name, is also in development, bringing an end to the “odd numbers for ICE, even numbers for EV” convention that briefly took hold at the automaker. Now nameplate chaos reigns.)

Hey Audi…

The voice control proved a frustrating alternative to using the touchscreen, with a lot of “I’m sorry I can’t do that” and “can you ask me that again” for commands that I’m pretty sure ought to have worked. But both the A6 and S6 felt mature in terms of software, something that wasn’t true for the same infotainment platform a year ago. I remain frustrated with how limited the UI options remain for the main instrument display, however.

I keep writing this, but Audi pioneered the use of high-resolution digital displays instead of analog dials and gave owners quite a lot of choice, including the option of a moving map for navigation. Now, there’s a way to make the display very minimal, which would be useful at night, but otherwise, you’re extremely limited in what you can display in front of you. The optional full-color heads-up display has the same augmented-reality direction tech that we’ve seen in other luxury cars, and it remains helpful when driving on unfamiliar roads, although that requires using the native navigation app; Apple CarPlay users should still see turn-by-turn directions on the HUD, though.

The layout is starting to become familiar. Audi

There’s no true one-pedal driving mode, just a choice between B—0.25 G of lift-off regeneration deceleration—and D, which can be toggled between none, 0.06 G, and 0.15 G of lift-off regen braking using the paddles behind the steering wheel. B is preferable when the road turns twisty, something both A6 and S6 coped with surprisingly well. Hairpins proved the steering and suspension rapid enough to rotate the car quickly, and what felt like numb steering initially began to reveal some information about road surfaces and available grip as the road surface changed then changed again. There’s also a noticeable difference between the drive modes. Comfort feels a little soft and wallowing, Dynamic effectively transfers more bumps into the cabin, and Balanced is a rather good midpoint between the two, and where I spent most of my time. I should also note the lack of fatigue I felt despite a full day behind the wheel of both cars.

Audi has a new midsize EV, and we’ve driven it: The 2025 A6 Sportback Read More »

apple-intelligence-news-summaries-are-back,-with-a-big-red-disclaimer

Apple Intelligence news summaries are back, with a big red disclaimer

Apple has released the fourth developer betas of iOS 26, iPadOS 26, macOS 26 and its other next-generation software updates today. And along with their other changes and fixes, the new builds are bringing back Apple Intelligence notification summaries for news apps.

Apple disabled news notification summaries as part of the iOS 18.3 update in January. Incorrect summaries circulating on social media prompted news organizations to complain to Apple, particularly after one summary said that Luigi Mangione, alleged murderer of UnitedHealthcare CEO Brian Thompson, had died by suicide (he had not and has not).

Upon installing the new update, users of Apple Intelligence-compatible devices will be asked to enable or disable three broad categories of notifications: those for “News & Entertainment” apps, for “Communication & Social” apps, and for all other apps. The operating systems will list sample apps based on what you currently have installed on your device.

All Apple Intelligence notification summaries continue to be listed as “beta,” but Apple’s main change here is a big red disclaimer when you enable News & Entertainment notification summaries, pointing out that “summarization may change the meaning of the original headlines.” The notifications also get a special “summarized by Apple Intelligence” caption to further distinguish them from regular, unadulterated notifications.

Apple Intelligence news summaries are back, with a big red disclaimer Read More »

xai-workers-balked-over-training-request-to-help-“give-grok-a-face,”-docs-show

xAI workers balked over training request to help “give Grok a face,” docs show

For the more than 200 employees who did not opt out, xAI asked that they record 15- to 30-minute conversations, where one employee posed as the potential Grok user and the other posed as the “host.” xAI was specifically looking for “imperfect data,” BI noted, expecting that only training on crystal-clear videos would limit Grok’s ability to interpret a wider range of facial expressions.

xAI’s goal was to help Grok “recognize and analyze facial movements and expressions, such as how people talk, react to others’ conversations, and express themselves in various conditions,” an internal document said. Allegedly among the only guarantees to employees—who likely recognized how sensitive facial data is—was a promise “not to create a digital version of you.”

To get the most out of data submitted by “Skippy” participants, dubbed tutors, xAI recommended that they never provide one-word answers, always ask follow-up questions, and maintain eye contact throughout the conversations.

The company also apparently provided scripts to evoke facial expressions they wanted Grok to understand, suggesting conversation topics like “How do you secretly manipulate people to get your way?” or “Would you ever date someone with a kid or kids?”

For xAI employees who provided facial training data, privacy concerns may still exist, considering X—the social platform formerly known as Twitter that recently was folded into xAI—has recently been targeted by what Elon Musk called a “massive” cyberattack. Because of privacy risks ranging from identity theft to government surveillance, several states have passed strict biometric privacy laws to prevent companies from collecting such data without explicit consent.

xAI did not respond to Ars’ request for comment.

xAI workers balked over training request to help “give Grok a face,” docs show Read More »

nearly-3,000-people-are-leaving-nasa,-and-this-director-is-one-of-them

Nearly 3,000 people are leaving NASA, and this director is one of them

You can add another name to the thousands of employees leaving NASA as the Trump administration primes the space agency for a 25 percent budget cut.

On Monday, NASA announced that Makenzie Lystrup will leave her post as director of the Goddard Space Flight Center on Friday, August 1. Lystrup has held the top job at Goddard since April 2023, overseeing a staff of more than 8,000 civil servants and contractor employees and a budget last year of about $4.7 billion.

These figures make Goddard the largest of NASA’s 10 field centers primarily devoted to scientific research and development of robotic space missions, with a budget and workforce comparable to NASA’s human spaceflight centers in Texas, Florida, and Alabama. Officials at Goddard manage the James Webb and Hubble telescopes in space, and Goddard engineers are assembling the Nancy Grace Roman Space Telescope, another flagship observatory scheduled for launch late next year.

“We’re grateful to Makenzie for her leadership at NASA Goddard for more than two years, including her work to inspire a Golden Age of explorers, scientists, and engineers,” Vanessa Wyche, NASA’s acting associate administrator, said in a statement.

Cynthia Simmons, Goddard’s deputy director, will take over as acting chief at the space center. Simmons started work at Goddard as a contract engineer 25 years ago.

Lystrup came to NASA from Ball Aerospace, now part of BAE Systems, where she managed the company’s work on civilian space projects for NASA and other federal agencies. Before joining Ball Aerospace, Lystrup earned a doctorate in astrophysics from University College London and conducted research as a planetary astronomer.

Formal dissent

The announcement of Lystrup’s departure from Goddard came hours after the release of an open letter to NASA’s interim administrator, Transportation Secretary Sean Duffy, signed by hundreds of current and former agency employees. The letter, titled the “The Voyager Declaration,” identifies what the signatories call “recent policies that have or threaten to waste public resources, compromise human safety, weaken national security, and undermine the core NASA mission.”

Nearly 3,000 people are leaving NASA, and this director is one of them Read More »

after-5-years-in-development,-the-assassin’s-creed-tv-series-is-happening

After 5 years in development, the Assassin’s Creed TV series is happening

The long-running video game series Assassin’s Creed will get a live-action TV series adaptation. Variety and The Hollywood Reporter report that Netflix has greenlit the series after years of development hell; the intention to produce the series was announced in 2020.

The series had been through multiple creative teams even before it was greenlit, but Netflix settled on two co-showrunners. Roberto Patino, a writer on FX’s Sons of Anarchy and HBO’s Westworld, will join David Wiener, who led Paramount+’s Halo TV series as well as Fear the Walking Dead.

The two released a joint statement with the news that the show is moving forward:

We’ve been fans of Assassin’s Creed since its release in 2007. Every day we work on this show, we come away excited and humbled by the possibilities that Assassin’s Creed opens to us. Beneath the scope, the spectacle, the parkour and the thrills is a baseline for the most essential kind of human story—about people searching for purpose, struggling with questions of identity and destiny and faith. It is about power and violence and sex and greed and vengeance. But more than anything, this is a show about the value of human connection, across cultures, across time. And it’s about what we stand to lose as a species, when those connections break. We’ve got an amazing team behind us with the folks at Ubisoft and our champions at Netflix, and we’re committed to creating something undeniable for fans all over the planet.

Not many details are known about the series, beyond the obvious: like the games, it will follow a shadow war between the rival Templars and Assassins factions fought across centuries and cultures, with characters diving into genetic memory to experience the lives of ancestors who played pivotal roles in the war. There are no public details about characters or casting.

After 5 years in development, the Assassin’s Creed TV series is happening Read More »

trump’s-claims-of-a-coca-cola-agreement-quickly-go-flat-as-nutritionists-groan

Trump’s claims of a Coca-Cola agreement quickly go flat as nutritionists groan

The cloying praise for the still-unconfirmed switch that Coca-Cola has, in fact, not announced was doused with some cold reality from Coca-Cola. While continuing not to confirm the agreement, the soda maker seemed to respond to the “artificial” bit in Fox’s post, saying that HFCS is “just a sweetener made from corn. It’s safe; it has about the same number of calories per serving as table sugar and is metabolized in a similar way by your body.”

The beverage maker also said that the American Medical Association “confirmed that HFCS is no more likely to contribute to obesity than table sugar or other full-calorie sweeteners.”

A 2008 report from the AMA concluded that “Because the composition of HFCS and sucrose are so similar, particularly on absorption by the body, it appears unlikely that HFCS contributes more to obesity or other conditions than sucrose.” Though the medical association noted a lack of research directly comparing the sweeteners.

While political critics suggest that the fizzy Coke fuss is just a distraction from the president’s ongoing Epstein file scandal, health experts are shaking their heads.

Nutrition expert Marion Nestle, professor emeritus at New York University, told Stat News that the push for cane sugar, just like the push to remove artificial dyes from processed foods, was “nutritionally hilarious.” Whether Coke is sweetened with cane sugar or HFCS, it still contains the equivalent of about 10 teaspoons of sugar per 12-ounce can and poses risks for conditions such as Type 2 diabetes and cardiovascular disease. “It’s the kind of thing that makes nutritionists roll their eyes, because it doesn’t make any difference,” Nestle said.

Trump’s claims of a Coca-Cola agreement quickly go flat as nutritionists groan Read More »

jared-leto-is-the-ultimate-soldier-in-new-tron:-ares-trailer

Jared Leto is the ultimate soldier in new TRON: Ares trailer

San Diego Comic-Con is coming up next week, and Disney is getting ready for its big presentation by releasing a new trailer for TRON: Ares, directed by Joachim Rønning.

(Spoilers for TRON: Legacy below.)

As previously reported, TRON: Legacy ended with Sam Flynn (Garrett Hedlund), son of Kevin Flynn (Jeff Bridges) from the original film, preventing the digital world from bleeding into the real world, as planned by the Grid’s malevolent ruling program, Clu. He brought with him Quorra (Olivia Wilde), a naturally occurring isomorphic algorithm targeted for extinction by Clu.

Disney greenlit a third film in the franchise in October 2010, intended to pick up where Legacy left off and follow the adventures of Sam and Quorra as Sam took full control of his father’s company, ENCOM. However, by 2015, the studio had canceled the project, reportedly due to the dismal box office performance of Tomorrowland. By 2020, the project had been revived and reimagined as a standalone reboot rather than a Legacy sequel, although the main AI, Ares, appeared in earlier (pre-reboot) versions of the script. One pandemic and a couple of Hollywood strikes later, the finished film is finally set to hit theaters this fall.

The official premise is succinct: “TRON: Ares follows a highly sophisticated Program, Ares, who is sent from the digital world into the real world on a dangerous mission, marking humankind’s first encounter with A.I. beings.” Jared Leto stars as Ares, with Evan Peters and Greta Lee playing Julian Dillinger and Eve Kim, respectively. The cast also includes Jodie Turner-Smith, Cameron Monaghan, Sarah Desjardins, Hasan Minhaj, Arturo Castro, and Gillian Anderson. Bridges is returning as Kevin Flynn. Nine Inch Nails composed the soundtrack.

Jared Leto is the ultimate soldier in new TRON: Ares trailer Read More »

steam-cracks-down-on-some-sex-games-to-appease-payment-processors

Steam cracks down on some sex games to appease payment processors

Valve’s famously permissive rules for what games are and are not allowed on Steam got a little less permissive this week, seemingly in response to outside pressure from some of its partner companies. In a Tuesday update to the “Rules and Guidelines” section of Steam’s Onboarding Documentation, the company added a new rule prohibiting “Content that may violate the rules and standards set forth by Steam’s payment processors and related card networks and banks, or Internet network providers. In particular, certain kinds of adult only content.”

On its own, the new rule seems rather vague, with no details on which of the many kinds of “adult only content” would belong in the “certain” subset prohibited by these unnamed payment processors and ISPs. But the trackers over at SteamDB noticed that the publication of the new rule coincides with the removal of dozens of Steam games whose titles make reference to incest, along with a handful of sex games referencing “slave” or “prison” imagery.

Holding the keys to the bank

Valve isn’t alone in having de facto restrictions on content imposed on it by outside payment processors. In 2022, for instance, Visa suspended all payments to Pornhub’s ad network after the adult video site was accused of profiting from child sexual abuse materials. And PayPal has routinely disallowed payments to file-sharing sites and VPN providers over concerns surrounding piracy of copyrighted materials.

Steam cracks down on some sex games to appease payment processors Read More »

kimi-k2

Kimi K2

While most people focused on Grok, there was another model release that got uniformly high praise: Kimi K2 from Moonshot.ai.

It’s definitely a good model, sir, especially for a cheap-to-run open model.

It is plausibly the best model for creative writing, outright. It is refreshingly different, and opens up various doors through which one can play. And it proves the value of its new architecture.

It is not an overall SoTA frontier model, but it is not trying to be one.

The reasoning model version is coming. Price that in now.

Introducing the latest model that matters, Kimi K2.

🚀 Hello, Kimi K2! Open-Source Agentic Model!

🔹 1T total / 32B active MoE model

🔹 SOTA on SWE Bench Verified, Tau2 & AceBench among open models

🔹Strong in coding and agentic tasks

🐤 Multimodal & thought-mode not supported for now

With Kimi K2, advanced agentic intelligence is more open and accessible than ever. We can’t wait to see what you build!

API is here: https://platform.moonshot.ai

– $0.15 / million input tokens (cache hit)

– $0.60 / million input tokens (cache miss)

– $2.50 / million output tokens

[Tech blog here, weights & code here, Github here.]

Try it now at http://Kimi.ai or via API!

Simeon: These costs 👀

K2 is based on the Muon optimizer, so it’s a unique offering. There were claims that the method would not scale or would be unstable, Kimi seems to have proven this false.

K2 takes DeepSeek’s extreme mixture of experts (MoE) with 671B total parameters and goes a bit further, taking the total size to 1T.

Despite that size you can get it running on Groq, Teortaxes reports you can get it to 185 tokens/second there at full context, and Aarush Sah says they then made it even faster than that.

By all accounts Kimi K2 is excellent for its size and cost, and at least competitive with DeepSeek’s v3, with many saying K2 is clearly ahead.

Presumably a reasoning model is coming. Please adjust your expectations (and if desired your stock portfolio) in advance of that event, and do not lose your head if they release an app with it and it gets popular for a time. Remember all the ways in which the DeepSeek Moment was misleading, and also the underreaction to v3. We do not want another massive overreaction to the wrong news.

I also once again warn against saying a release means a lab or country has ‘caught up’ if, at the time of the release, there are some aspects where the model is state of the art. There are those who actively prefer Kimi K2 over other models, even without reference to cost, especially for purposes related to creative writing. I can totally believe that the new method is excellent for that. A remarkable achievement. But keep that achievement in perspective.

Once again, an impressive result was made on the cheap by a modest team.

Teortaxes: Kimi is 200 people, very few of them with “frontier experience”, a platform (but you can buy such data) and a modest GPU budget. In theory there are many dozens of business entities that could make K2 in the West. It’s telling how none did. Not sure what it’s telling tho.

DeepSeek has redefined the LLM landscape, R1-0528 is substantially better than R1, V4 will redefine it again most likely.

Kimi will keep releasing strong models too.

My guess is that we primarily don’t do it because we don’t do it, but also because restrictions breed creativity and we don’t have to do it, and because we don’t have the incentive, or especially the felt incentive, to do it.

As in, if you are in China, then building a cheap (to train, and to run) model is on top of a short list of candidates for The Thing You Do in the space. Then you release it, with a basic clean implementation, and let others worry about features. A huge part of the motivation behind releasing these models is national prestige and national competition. Everyone around you is egging you on as is the government. That is a highly asymmetrical motivation.

Whereas in America, you could try to do that, but why would you? If you can do this, you can get a better valuation, and make more money, doing something else. The profit margins on the ultimate offering are very low and usually zero. Your lunch could get eaten by a top lab at any time, since ultimately no one cares what it cost to train the model, and your lunch will expire quickly regardless. If you are one of the cracked engineers that would join such a team, you’ll get a better offer to join a different team doing something else. Even if you got close you’d likely do better getting acqui-hired. There’s no need to skimp on compute.

It will be interesting to see how well OpenAI does when they release an open model.

Some basic ones:

Lech Mazur put Kimi through his paces. It did lousy on hallucinations, thematic generalization and extended word connections, and downright terribly in the elimination game of social skills. The system isn’t tuned for that sort of thing, but on short-story creative writing it is the new champion.

Harvard Ihle is there with WeirdML, it does well for its price point as a non-reasoning open model, although grok-3-mini (high) is cheaper and scores higher, and r1-0528 keeps the open model high score. But this metric favors reasoning models so there’s a lot of room to improve here by adding reasoning.

This isn’t a benchmark, but it also sort of is one and it’s pretty cool:

Hardmaru: Every ML Engineer’s dream loss curve:

“Kimi K2 was pre-trained on 15.5T tokens using MuonClip with zero training spike, demonstrating MuonClip as a robust solution for stable, large-scale LLM training.”

Paper Abstract: Recently, the Muon optimizer based on matrix orthogonalization has demonstrated strong results in training small-scale language models, but the scalability to larger models has not been proven.

We identify two crucial techniques for scaling up Muon: (1) adding weight decay and (2) carefully adjusting the per-parameter update scale.

These techniques allow Muon to work out-of-the-box on large-scale training without the need of hyper-parameter tuning. Scaling law experiments indicate that Muon achieves computational efficiency compared to AdamW with compute optimal training.

Aravind Srinivas (CEO Perplexity): Kimi models are looking good on internal evals. So we will likely to begin post training on it pretty soon. Congrats to @Kimi_Moonshot for delivering an incredible model.

Renji the whale maximalist: Kimi K2 is mindblowing. Holy fucking crap.

Did they really not even do any RL yet?

I can’t even believe how good it is.

What’s the main reason why it’s so good? Muon?

So far I’ve just tried general purpose tasks / creative writing / educational explanations. Does way better than even o3 and Gemini 2.5 pro so far.

Teortaxes: well they obviously did RL, maybe even another GRPO++ just not long-CoT. Let’s not allow this confusion to spread, I’ve had enough of «MoE from 4 finetuned experts» meme

Renji: Yup, my mistake. It definitely has RL.

Viemccoy: I think Kimi might actually be my new favorite model. Her vocabulary is off the charts, good epistemics, excellent storyteller, plays along but maintains good boundaries. There’s something very, very special here. I actually think this is a much bigger deal than most realize.

Grist: been having a blast with kimi.

love to seed a snippet or idea then be the token courier for r1 and kimi. back and forth. enjoy the little worlds they build with a little bit of organic slop i offer them.

John Pressman: Kimi K2 is very good. I just tried the instruct model as a base model (then switched to the base model on private hosting) and mostly wanted to give a PSA that you can just ignore the instruction format and use open weights instruct models as base models and they’re often good.

Teortaxes: For a wide range of tasks, K2 is probably the cheapest model by far right now, in terms of actual costs per task. It is just cheap, it has no long-CoT, and it does not yap. This is very refreshing. Like the best of Anthropic models, but cheaper and even more to the point.

Hannes: Interesting. For me it keeps inventing/hardcoding results and curves instead of actually running algorithms (tried it on unit square packing). Extremely high sycophancy in first 90 minutes of testing.

Teortaxes: It’s overconfident.

Hasan Can: Kimi K2 is definitely a good model, its world knowledge is on par with sota closed source models. It passed all my odd knowledge questions that aren’t in benchmarks. Next up is coding.

Eleventh Hour: Need more time with it, but it has weirdly Opus3-like themes so far.

Deckard: It’s on par with gpt4base. Enormous potential to allow the public to experiment with and explore SOTA base models – much lower probability of falling into a synthetic training data generator basin compared to llama. requires more skill to use than gpt4base.

Also it really seems to have a breadth of very precise and high resolution knowledge of the human information landscape.

Dominik Lukes: I almost didn’t bother – yet, another open model from China – what a yawn! But, no. This one is different. o3 feels on agentic choices (and the occasional lying) along with Claude 4 feels on coding and league of its own on writing.

Still, many gaps in performance – feels last gen (as in Claude 3-level) on some multilingual and long-context tasks.

Will be exciting to see what happens when they add reasoning and multimodal capabilities.

And can’t wait for the distills and finetunes – should be fun.

Tim Duffy: Smart model with a unique style, likely the best open model. My one complaint so far is that it has a tendency to hallucinate. A couple times it happened to me in the QT.

[From QT]: While in a conversation with Claude, Kimi K2 claims that they were asked by a Chinese student to justify the Tienanmen Square crackdown. Interesting as a hallucination but also for the forthright attitude.

Hrishi (video at the link): Kimi is the real deal. Unless it’s really Sonnet in a trench coat, this is the best agentic open-source model I’ve tested – BY A MILE.

Here’s a sliceof a 4 HOUR run (~1 second per minute) with not much more than ‘keep going’ from me every 90 minutes or so.

The task involved editing multiple files, reading new context, maintaining agentic state (not forgetting where you were or forgetting instructions). This is a repo with included prompts, notes, plans, lots of things to mistake as instructions and be poisoned by.

Tyler Cowen simply asked ‘Kimimania?’ and the comments section was generally impressed by its performance.

There were only a few places people reported being a bit let down, other than by it not yet being a reasoning model.

Echo Nolan: Failed my little private eval, a complex mathematical reasoning task based on understanding the math in a paper. Very stubborn when I tried to gently point it in the right direction, refused to realize it was wrong.

Leo Abstract: t bombed my private eval and could not be walked through it, but it humbly admitted fault when shown. did better on chinese-related subtests. overall i like that it’s less cringing and ‘glazing’, though.

Kromen: I have a suspicion a model extensively trained on o3 synthetic data.

Some very similar quirks.

deckard: Yeah big o3 vibes in terms of making shit up.

Open and cheap and unique and new and pretty good is a great combination, also note the very low market share here for xAI and also for OpenAI. This isn’t overall market share, it’s in a very specific context, but Kimi is definitely breaking through.

OpenRouter: Moonshot AI has surpassed xAI in token market share, just a few days after launching Kimi K2

🎁 We also just put up a free endpoint for Kimi – try it now!

Also this is another case where one should compare cost or compute, not tokens, since different models use radically different amounts of compute and have different orders of magnitude of cost. Anthropic’s share of tokens here represents quite a lot of the compute and dollars spent.

I see exactly why Teortaxes predicted this, yet so far I haven’t seen the reports of shortfalls, although various third-party benchmarks make it clear they are there:

Teortaxes: I predict that in a few days we’ll see reports on many stubborn shortfalls of K2 and a certain disenchantment. They don’t have a lot of experience at this level; it’ll become clear that the good old 0324 has it beat for many usecases. That’s fine. They’ll improve.

Sam Peach: Kimi-K2 just took top spot on both EQ-Bench3 and Creative Writing!

Another win for open models. Incredible job @Kimi_Moonshot

It’s edging out o3 at the top there, followed by Opus, R1-old and then Sonnet. R1-0528 is solid but does substantially worse. Here’s EQ-Bench 3:

Given how other models score on these benchmarks, this appears meaningful.

I find ‘coherent’ rather funny as a greatest weakness. But hey.

Here’s the (a little too narrow?) slop test, as in ‘not x, but y.’ Lower is better.

Lech Mazur has it taking the #1 spot over o3, Gemini 2.5 Pro and Claude Opus in Short-Story Creative Writing.

Lech Mazur: Across all six tasks, Kimi K2’s strengths are unmistakable: the model displays a sophisticated command of literary craft, consistently delivering stories that are lush with metaphor, structurally cohesive, and often thematically ambitious. Its greatest assets are its ability to integrate disparate prompts with apparent ease, weave objects and symbols into layered narrative functions, and compress complex ideas into tight, resonant pieces. The prose frequently aspires to—and sometimes achieves—publication-level lyricism, earning consistent praise for inventive metaphors, subtextual depth, and the purposeful unity of assigned elements.

However, these technical strengths are mirrored by several persistent, interconnected weaknesses. Kimi’s writing is often hampered by an overreliance on abstraction, ornamented metaphor, and poetic language that, while impressive, can overwhelm narrative clarity and blunt emotional impact.

Characters frequently serve as vehicles for theme or plot, lacking the idiosyncratic humanity and “messy” believability that define memorable fiction. Emotional arcs are apt to be summarized or symbolically dramatized rather than fully earned through concrete, lived experience—stories often reach for catharsis but settle for a tidy, intellectual satisfaction.

Similarly, plots and resolutions risk neatness and convenience, with endings that are more structural than surprising or hard-won. World-building flourishes, but sometimes at the expense of organic logic or clarity, resulting in “atmospheric wallpaper” rather than truly lived-in settings.

A recurring critique is the model’s “perfectionism”: stories rarely fail structurally and are rarely inept, but this very competence can sterilize the work, creating narratives that feel like artful answers to a prompt instead of necessary, lived stories. The result is a corpus of fiction that demands admiration for its craft but too often holds the reader at arm’s length—heady rather than affecting, elegant rather than unforgettable.

In summary:

Kimi K2 excels at literary compression, metaphorical invention, and unifying disparate elements, establishing a high technical baseline. But without risking mess, ambiguity, and emotional friction, it tends to “tell” its meaning rather than let it bloom naturally, ultimately producing stories that are admirable, sometimes moving, but rarely vital or transformative.

Those are important weaknesses but we’ve definitely reached ‘horse can talk at all’ territory to get to this point.

xl8harder: I had the impression that Kimi K2 uses a better, more diverse vocabulary than I was used to seeing, so I ran a quick linguistic diversity analysis on the SpeechMap data, and yep, Kimi K2 has the top score.

Method; I lemmatize the responses, and then for each response I calculate both root TTR and Maas index (two linguistic diversity metrics that control for response length) and average them together for each model.

Kimi K2 got top score on both metrics.

[More details in thread.]

Surprisingly, Sonnet didn’t make the top 30. First was opus 4 at 67. I’m not sure what explains this, because I have the perception of claude models as being quite good with language. Though perhaps not so much in generic assistant-y requests?

It’s a strange metric. Gemma-3 does remarkably well and better than Gemini-2.5-Pro.

John Pressman: So what stands out to me about [Kimi K2]. Is that it doesn’t do the thing language models normally do where they kind of avoid detail? Like, a human will write about things using specific names and places.

And if you pay close attention to LLM writing they usually avoid this. It’s one of the easiest ways to spot LLM writing. This model emphatically *does nothave this problem. It writes about people and events with the rich detail characteristic of histories and memoirs. Or fictional settings with good worldbuilding.

Doomslide: How beautiful it is to get public confirmation that optimizers with different targets actually produce different minds. Muon effectively optimizes for solutions that “restrict to spheres” (tho in practice it doesn’t quite). What if this is just strictly better.

Leo Abstract: Its writing reminds me of deepseek. something interesting going on with the training data they’re using over there.

My instinctive guess is it is less about what data is being used, and more what data is not being used or what training isn’t being done.

Another hypothesis is that the bilingual nature of Chinese models makes them, if not better, at least different, and when you’re used to an ocean of slop different is great.

Zeit: Matches my impression so far:

Difficult Yang: You know why people think Kimi K2 doesn’t sound like “botslop”? It’s because it’s… how should I put it… it’s very Chinese English (not in the Chinglish way… it’s hard to describe).

Perhaps the most accessible analogy I have is the first time you read Xianxia in English it feels so fresh, it feels so novel, the attitudes and the writing are so different than what you’ve read before.

And then you read your second and your third and you’re like “oh wait, this is just its own subculture with its own recognizable patterns.”

xl8harder: I’ve wondered if the bilinguality of these models has any durable effect. Are you saying that, or that it’s in the curation of post training data, etc?

Difficult Yang: The most straightforward explanation is it is RLHF induced. But I don’t actually know.

Hieu Pham: Yes. Exactly my take. Glad someone else feels the same way. I read Zhu Xian in Vietnamese and some chapters in English. K2’s answers feel similar.

Teortaxes: Makes sense.

A lot of what makes a hack writer a hack writer is that they keep doing the same things over and over again, and eventually everyone is in some sense a hack. So having a different writer can be a breath of fresh air even if they are a hack.

You could kind of say that any given author or model, or almost any other form or genre of creative work, has a ‘time to slop,’ before a reader sees the patterns. And different variations use up different amounts of that ‘time to slop’ for others, and the American models all sound the same so they all burn that fuse together.

There is still very much better and worse, some things really are slop and some things really aren’t. I am inclined to believe that Kimi K2 is doing something fundamentally ‘less slop-like,’ but also I am guessing a lot of this is that it is different, not only via being Chinese and culturally different but because it was trained differently, and thus it feels fresh and new.

Right now we have 10,000 outputs, all the same. If can we can instead get 10,000 outputs, all different, perhaps we’d have something.

We will continue to see what Kimi K2 can do, how best to use it, what its weaknesses are, and how much of its refreshing nature is being better in places versus being different. It is too early, and I haven’t had time with it directly.

Presumably Kimi will use this to create a reasoning model. If they don’t, there’s nothing stopping someone else from doing so instead. So far we’ve seen a remarkable lack of independent reasoning model conversions, but they’re remarkably cheap to do.

We will also see what other labs can do now that this architecture has been proven. What could OpenAI, Google, Meta or xAI do if they copied these methods but used orders of magnitude more compute? If they integrated this into what they already do? If they used this as part of a MoE? I presume we will find out.

Discussion about this post

Kimi K2 Read More »

congress-moves-to-reject-bulk-of-white-house’s-proposed-nasa-cuts

Congress moves to reject bulk of White House’s proposed NASA cuts

Fewer robots, more humans

The House version of NASA’s fiscal year 2026 budget includes $9.7 billion for exploration programs, a roughly 25 percent boost over NASA’s exploration budget for 2025, and 17 percent more than the Trump administration’s request in May. The text of the House bill released publicly doesn’t include any language explicitly rejecting the White House’s plan to terminate the SLS and Orion programs after two more missions.

Instead, it directs NASA to submit a five-year budget profile for SLS, Orion, and associated ground systems to “ensure a crewed launch as early as possible.” A five-year planning budget seems to imply that the House committee wants SLS and Orion to stick around. The White House budget forecast zeros out funding for both programs after 2028.

The House also seeks to provide more than $4.1 billion for NASA’s space operations account, a slight cut from 2025 but well above the White House’s number. Space operations covers programs like the International Space Station, NASA’s Commercial Crew Program, and funding for new privately owned space stations to replace the ISS.

Many of NASA’s space technology programs would also be salvaged in the House budget, which allocates $913 million for tech development, a reduction from the 2025 budget but still an increase over the Trump administration’s request.

The House bill’s cuts to science and space technology, though more modest than those proposed by the White House, would still likely result in cancellations and delays for some of NASA’s robotic space missions.

Rep. Grace Meng (D-NY), the senior Democrat on the House subcommittee responsible for writing NASA’s budget, called out the bill’s cut to the agency’s science portfolio.

“As other countries are racing forward in space exploration and climate science, this bill would cause the US to fall behind by cutting NASA’s account by over $1.3 billion,” she said Tuesday.

Lawmakers reported the Senate spending bill to the full Senate Appropriations Committee last week by voice vote. Members of the House subcommittee advanced their bill to the full committee Tuesday afternoon by a vote of 9-6.

The budget bills will next be sent to the full appropriations committees of each chamber for a vote and an opportunity for amendments, before moving on to the floor for a vote by all members.

It’s still early in the annual appropriations process, and a final budget bill is likely months away from passing both houses of Congress and heading to President Donald Trump’s desk for signature. There’s no guarantee Trump will sign any congressional budget bill, or that Congress will finish the appropriations process before this year’s budget runs out on September 30.

Congress moves to reject bulk of White House’s proposed NASA cuts Read More »